Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Axios Vitals on MSN3d
PBMs made more than $7B marking up specialty generics: FTCThe three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Pharmacy advocate groups are teaming up with lawmakers to get new legislation passed to stop monopolistic behaviors from ...
House Energy Chair Brett Guthrie said he hopes to revive the health legislation that was pushed out of the American Relief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback